AZD2563, a novel oxazolidinone: Definition of antibacterial spectrum, assessment of bactericidal potential and the impact of miscellaneous factors on activity in vitro

Clinical Microbiology and Infection

Volumn 10, Issue 3, 2004, Pages 247-254

  Wookey, A ^a   Turner, Philip J ^a   Greenhalgh, J M ^a   Eastwood, M ^a   Clarke, J ^a   Sefton, C ^a  

^a ASTRAZENECA   (United Kingdom)

Author keywords

Bactericidal activity; Bacteriostatic activity; In vitro properties; MICs; Oxazolidinones

Indexed keywords

CLARITHROMYCIN; COAGULASE; DALFOPRISTIN PLUS QUINUPRISTIN; LEVOFLOXACIN; LINEZOLID; OXAZOLIDINONE DERIVATIVE; POSIZOLID; TEICOPLANIN; VANCOMYCIN;

AEROBIC BACTERIUM; ANTIBACTERIAL ACTIVITY; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIOSTASIS; BACTERIUM ISOLATE; COAGULASE NEGATIVE STAPHYLOCOCCUS; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; CORYNEBACTERIUM; DRUG EFFICACY; ENTEROCOCCUS; GRAM NEGATIVE BACTERIUM; GRAM POSITIVE BACTERIUM; HAEMOPHILUS; IN VITRO STUDY; INOCULATION; MINIMUM INHIBITORY CONCENTRATION; MORAXELLA; NONHUMAN; PH; PRIORITY JOURNAL; STAPHYLOCOCCUS AUREUS; STREPTOCOCCUS PNEUMONIAE; STRUCTURE ACTIVITY RELATION;

BACTERIA (MICROORGANISMS); CORYNEBACTERIUM; ENTEROBACTERIACEAE; ENTEROCOCCUS; HAEMOPHILUS; NEGIBACTERIA; POSIBACTERIA; STAPHYLOCOCCUS; STAPHYLOCOCCUS AUREUS; STREPTOCOCCUS; STREPTOCOCCUS PNEUMONIAE;

EID: 1642360174     PISSN: 1198743X     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1198-743X.2004.00770.x     Document Type: Article

References (29)

1. Panlilio AL, Culver DH, Gaynes RP et al. Methicillin-resistant S. aureus in US hospitals, 1975-1991. Infect Control Hosp Epidemiol 1992; 13: 582-586.
2. Centers for Disease Control and Prevention. Update: Staphylococcus aureus with reduced susceptibility to vancomycin - US 1997. MMWR 1997; 46: 813-815.
3. Moellering RC. Vancomycin-resistant enterococci. Clin Infect Dis 1998; 26: 1196-1199.
4. Doern GV, Pfaller MA, Kugler K et al. Prevalence of antimicrobial resistance among respiratory tract isolates of Streptococcus pneumoniae in North America: 1997 results from the SENTRY Antimicrobial Surveillance programme. Clin Infect Dis 1998; 27: 764-768.
5. Gravestock MB, Betts MJ, Chawner E et al. In vivo studies of novel oxazolidinones with O- and N-linked C-5 heterocyclic side-chains, including AZD2563. [abstract F-1023]. In: Program and abstracts of the 41st Interscience Conference on Antimicrobial Agents and Chemotherapy, Chicago, IL. Washington, DC: American Society for Microbiology, 2001; 222.
6. Craig WA, Andes DR. Pharmacodynamic characteristics of AZD2563, the new oxazolidinone, in a murine thigh-infection model [abstract F-1037]. In: Program and abstracts of the 41st Interscience Conference on Antimicrobial Agents and Chemotherapy, Chicago, IL. Washington, DC: American Society for Microbiology, 2001; 226.
7. Andes DR, Craig WA. In vivo pharmacodynamic activity of AZD2563, the new oxazolidinone against multiple bacterial pathogens [abstract F-1038]. In: Program and abstracts of the 41st Interscience Conference on Antimicrobial Agents and Chemotherapy, Chicago, IL. Washington, DC: American Society for Microbiology, 2001; 226.
8. Hiramatsu K. The emergence of Staphylococcus aureus with reduced susceptibility to vancomycin in Japan. Am J Med 1998; 104: 7S-10S.
9. National Committee for Clinical Laboratory Standards. Methods for dilution antimicrobial tests for bacteria that grow aerobically, 5th edn. Approved standard M7-A5. Villanova, PA: NCCLS, 2000.
10. Wise R, Andrews JM, Boswell FJ, Ashby JP. The in-vitro activity of linezolid (U-100766) and tentative breakpoints. J Antimicrob Chemother 1998; 42: 721-728.
11. Kaatz GW, Seo SM. In vitro activities of oxazolidinone compounds U100592 and U100766 against Staphylococcus aureus and Staphylococcus epidermidis. Antimicrob Agents Chemother 1996; 40: 799-801.
12. Zurenko GE, Ford CW, Hutchinson DK, Brickner SJ, Barbachyn MR. Oxazolidinone antibacterial agents: Development of clinical candidates eperozolid and linezolid. Expert Opin Invest Drugs 1997; 6: 151-158.
13. Lin G, Clark CL, Jacobs MR, Appelbaum PC. Time-kill analysis of the antipneumococcal activity of AZD2563, the new oxazolidinone, compared to six other agents [abstract F-1033]. In: Program and abstracts of the 41st Interscience Conference on Antimicrobial Agents and Chemotherapy, Chicago, IL. Washington, DC: American Society for Microbiology, 2001; 224.
14. National Committee for Clinical Laboratory Standards. Methods for determining bactericidal activity of antimicrobial agents. Approved guideline M26-A. Villanova, PA: NCCLS, 2000.
15. Johnson AP, Warner M, Parsons T, Livermore DM. In vitro activity of a novel oxazolidinone, AZD2563, against Gram-positive cocci, including diverse multi-resistant isolates [abstract F-1026]. In: Program and abstracts of the 41st Interscience Conference on Antimicrobial Agents and Chemotherapy, Chicago, IL. Washington, DC: American Society for Microbiology, 2001; 223.
16. Fluit AC, Milatovic D, Verhoef J. Activity of AZD2563, the novel oxazolidinone, against European Gram-positive cocci [abstract F-1027]. In: Program and abstracts of the 41st Interscience Conference on Antimicrobial Agents and Chemotherapy, Chicago, IL. Washington, DC: American Society for Microbiology, 2001; 223.
17. Okamoto R, Sato Y, Hosaka R, Nakano S, Kaieda S, Inoue M. In vitro activity of AZD2563, the new oxazolidinone, against clinical isolates of Gram-positive cocci, including multi-resistant strains [abstract F-1028]. In: Program and abstracts of the 41st Interscience Conference on Antimicrobial Agents and Chemotherapy, Chicago, IL. Washington, DC: American Society for Microbiology, 2001; 223.
18. Jones RN, Anderegg TR, Biedenbach DJ, Pfaller MA. In vitro antimicrobial activity of AZD2563, a novel oxazolidinione, tested against Staphylococcus aureus and coagulase-negative staphylococci [abstract F-1029]. In: Program and abstracts of the 41st Interscience Conference on Antimicrobial Agents and Chemotherapy, Chicago, IL. Washington, DC: American Society for Microbiology, 2001; 224.
19. Anderegg TR, Biedenbach DJ, Jones RN. Antistreptococcal activity of AZD2563, a new oxazolidinone antimicrobial agent [abstract F-1030]. In: Program and abstracts of the 41st Interscience Conference on Antimicrobial Agents and Chemotherapy, Chicago, IL. Washington, DC: American Society for Microbiology, 2001; 224.
20. Baum SE, Jorgensen JH, Crawford SA, McElmeel ML. Activity of the new oxazolidinone, AZD2563, against selected recent North American isolates of Streptococcus pneumoniae [abstract F-1031]. In: Program and abstracts of the 41st Interscience Conference on Antimicrobial Agents and Chemotherapy, Chicago, IL. Washington, DC: American Society for Microbiology, 2001; 224.
21. Peric M, Clark CL, Lin G, Jacobs MR, Appelbaum PC. Antipneumococcal activity of AZD2563, a new oxazolidinone, compared with seven other agents [abstract F-1032]. In: Program and abstracts of the 41st Interscience Conference on Antimicrobial Agents and Chemotherapy, Chicago, IL. Washington, DC: American Society for Microbiology, 2001; 224.
22. Eliopoulos GM, Wennersten CB, Moellering RC. Comparative in vitro activity of the new oxazolidinone, AZD2563, against enterococci [abstract F-1034]. In: Program and abstracts of the 41st Interscience Conference on Antimicrobial Agents and Chemotherapy, Chicago, IL. Washington, DC: American Society for Microbiology, 2001; 225.
23. Anderegg TR, Jones RN, Howard WJ, Biedenbach DJ. In vitro evaluation of AZD2563, a new oxazolidinone, tested against unusual Gram-positive species [abstract F-1035]. In: Program and abstracts of the 41st Interscience Conference on Antimicrobial Agents and Chemotherapy, Chicago, IL. Washington, DC: American Society for Microbiology, 2001; 225.
24. Ednie L, Jacobs MR, Appelbaum PC. Anti-anaerobe activity of AZD2563, a new oxazolidinone, compared to 8 other agents [abstract F-1036]. In: Program and abstracts of the 41st Interscience Conference on Antimicrobial Agents and Chemotherapy, Chicago, IL. Washington, DC: American Society for Microbiology, 2001; 225.
25. Jones RN, Johnson DM, Erwin ME. In-vitro antimicrobial activities and spectra of U-100592 and U-100766, two novel fluorinated oxazolidinones. Antimicrob Agents Chemother 1996; 40: 720-726.
26. Mulazimoglu L, Drenning SD, Yu VL. In-vitro activities of two novel oxazolidinones (U-100592 and U-100766), a new fluoroquinolone (trovafloxacin), and dalfopristin-quinupristen against Staphylococcus aureus and Staphylococcus epidermidis. Antimicrob Agents Chemother 1996; 40: 2428-2430.
27. Zurenko GE, Yagi BH, Schaadt RD et al. In-vitro activities of U-100592 and U-100766, novel oxazolidinone antibacterial agents. Antimicrob Agents Chemother 1996; 40: 839-845.
28. Bostic GD, Perri MB, Thal LA, Zervos MJ. Comparative in-vitro and bactericidal activity of oxazolidinone antibiotics against multidrug-resistant enterococci. Diagn Microbiol Infect Dis 1998; 30: 109-112.
29. Anderegg TR, Jones RN, the Quality Control Study Group. Determination of disk diffusion and MIC quality control parameters for AZD2563, a novel long-acting oxazolidinone. Diagn Microbiol Infect Dis 2003; 45: 73-76.